TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28975664
Drug: Furosemide q12h
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide q12h (median dose = 1.39 mg/kg q12h; range = 0.70–6.30 mg/kg q12h)
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type A SSNHL (acute in low tone frequencies) with FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type B SSNHL (acute in high tone frequencies) with FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type C SSNHL (acute in all frequencies) with FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type D SSNHL (total deafness) with FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type A SSNHL without FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type B SSNHL without FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type C SSNHL without FEF
Study: 26695795
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for type D SSNHL without FEF
Study: 23995661
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs)
Study: 21411411
Drug: 1% Glechoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Glechoma hederacea extract lotion applied topically for 8 weeks
Study: 19153829
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (L + C)
Study: 11402116
Drug: Local methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local methylprednisolone injection (15 mg)
Study: 11402116
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (low-dose, short-term)
Study: 3525866
Drug: Diethylstilbestrol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (1 mg. 3 times daily)
Study: 3525866
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (280 mg. twice daily for 8 weeks and 140 mg. twice daily thereafter)
Study: 30304120
Drug: One implant
Normalized name: Testosterone Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One implant (GI)
Study: 30304120
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants (GII)
Study: 16648508
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 mg every 2 hours as needed, maximum of four capsules a day for 7 days)
Study: 16648508
Drug: Placebo (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (every 2 hours as needed, maximum of four capsules a day for 7 days)
Study: 16249975
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg/day, p.o.
Study: 16249975
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg/day, p.o. + famotidine 40 mg/day, p.o.
Study: 16249975
Drug: Rabeprazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole treatment (before treatment)
Study: 16249975
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (before treatment)
Study: 11729332
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) every-other-day
Study: 3119340
Drug: Nitroglycerin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.5 mg)
Study: 27966192
Drug: SDM intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SDM intervention (12-h SDM training program for physicians in combination with decision board use)
Study: 27595402
Drug: Transperineal prostatic
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal prostatic block (TPPB) with 10 ml 2% prilocaine (Group-I)
Study: 27595402
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (10 ml 2% lidocaine) followed by periprostatic nerve blockage (PPNB) with 10 ml 2% prilocaine (Group-II)
Study: 18689371
Drug: Daily 500
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 500 mcg phylloquinone supplementation for 3 years
Study: 15331394
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) + oral placebo
Study: 15331394
Drug: Diacerein 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 100 mg/day + IA injections of saline solution
Study: 15331394
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo + IA injections of saline solution
Study: 11425926
Drug: Interferon-beta-1a, 22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta-1a, 22 mcg tiw
Study: 11425926
Drug: Interferon-beta-1a, 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta-1a, 44 mcg tiw
Study: 2441162
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg S-9780
Study: 2441162
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg S-9780
Study: 2441162
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg S-9780
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation at 50 mg/kg
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation at 100 mg/kg
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation at 300 mg/kg
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation at 500 mg/kg
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation at 56.3 mg/kg
Study: 28484897
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin E supplementation from 56.3 to 588.4 mg/kg
Study: 26559363
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for depression group
Study: 26559363
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for schizophrenia group
Study: 24474233
Drug: Mesalazine (Pentasa®)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine (Pentasa®) 2 g sachet once daily
Study: 24474233
Drug: Mesalazine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (twice daily in tablets)
Study: 21199957
Drug: Bupropion treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion treatment for 8 weeks
Study: 10919933
Drug: High-isoflavone dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone dietary treatment
Study: 10919933
Drug: Low-isoflavone dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone dietary treatment
Study: 31922372
Drug: Magnetic seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic seizure therapy (high frequency 100 Hz, medium frequency 50 or 60 Hz, low frequency 25 Hz)
Study: 31922372
Drug: Magnetic seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic seizure therapy (high frequency over vertex)
Study: 28095051
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Treatment and Control)
Study: 15109188
Drug: Vital capacity
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital capacity rapid inhalation induction at 8% sevoflurane (Group VC8)
Study: 15109188
Drug: Vital capacity
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital capacity rapid inhalation induction at 4.5% sevoflurane (Group VC4.5)
Study: 15109188
Drug: Conventional stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stepwise inhalation induction (Group C)
Study: 11687365
Drug: Topical plus
Normalized name: Revolution Plus Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical plus intracameral anesthesia
Study: 9174114
Drug: LY293111 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY293111 48 mg
Study: 9174114
Drug: LY293111 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY293111 200 mg
Study: 7697690
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/d for 4 weeks
Study: 7697690
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/d for 4 weeks
Study: 7697690
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/d for 6 months
Study: 7697690
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every other day for 6 months
Study: 3310639
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (800 mg elemental calcium per day)
Study: 3310639
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (800 mg elemental calcium per day)
Study: 28603176
Drug: BM-MNC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM-MNC treatment
Study: 24176229
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg choline daily for 9 months
Study: 18077211
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure (nCPAP) treatment
Study: 9864075
Drug: Fluvoxamine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 300 mg/day + Placebo
Study: 9864075
Drug: Fluvoxamine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 300 mg/day + Pindolol 7.5 mg/day
Study: 7838642
Drug: Rapid injection
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid injection of indomethacin (3 doses)
Study: 7838642
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of indomethacin (over 36 hours)
Study: 687017
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without ECMO
Study: 25257273
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (oral antibiotics, mometasone furoate nasal spray, leukotriene receptor antagonist, mucoactive medications) for 3 months
Study: 25257273
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (drug therapy plus negative pressure of sputum aspiration) for 3 months
Study: 25257273
Drug: Coblation adenotonsillectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coblation adenotonsillectomy after 3 days conservative treatment and postoperative drug therapy for 2 weeks (B2 subgroup)
Study: 25257273
Drug: Coblation adenotonsillectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coblation adenotonsillectomy after 2 weeks conservative treatment and postoperative drug therapy for 3 months (B3 subgroup)
Study: 25257273
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy for 3 months (A1 subgroup)
Study: 25257273
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for 3 months (B1 subgroup)
Study: 7641173
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of ioversol 320 mg I/ml
Study: 7641173
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of ioversol 320 mg I/ml
Study: 7641173
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of ioversol 320 mg I/ml
Study: 7641173
Drug: 120 ml
Normalized name: 120 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 ml of ioversol 320 mg I/ml
Study: 22728911
Drug: SMS reminder
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminder at 10-12 weeks post-treatment
Study: 18755220
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of PEG-IFN alpha-2b and boceprevir
Study: 17145598
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g four times daily for 14 days
Study: 8719187
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg bolus followed by 0.20 mg/kg‐1/min‐1 infusion)
Study: 8719187
Drug: Midazolam (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (90 micrograms/kg 2 min before induction) followed by half-strength propofol (1 mg/kg bolus with 0.10 mg/kg‐1/min‐1 infusion)
Study: 22728633
Drug: Lactobacillus salivarius
Normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus salivarius (4x10^9 colony forming units/g daily for 12 weeks)
Study: 19951274
Drug: Rivastigmine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (up to 9 mg/day)
Study: 19036143
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy with Paclitaxel (50 mg/m2) and Carboplatin (AUC = 2) followed by surgery
Study: 12970783
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction chemotherapy regimen (TAD 2+7) with GM-CSF
Study: 12970783
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction chemotherapy regimen (TAD 2+7) without GM-CSF
Study: 2052056
Drug: Acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4000 mg per day)
Study: 2052056
Drug: Ibuprofen (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (low dose, 1200 mg per day)
Study: 2052056
Drug: Ibuprofen (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (high dose, 2400 mg per day)
Study: 28556500
Drug: Anti-TNF-alpha therapy
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-alpha therapy in Group I (n = 15)
Study: 28556500
Drug: PSG parameters
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSG parameters at third month of anti-TNF-alpha therapy in Group I
Study: 23571259
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with Ologen implant
Study: 20100913
Drug: Pamapimod (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamapimod (300 mg once daily for 10 days)
Study: 17445309
Drug: One-day prophylactic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day prophylactic antibiotic
Study: 17445309
Drug: Three-day prophylactic
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day prophylactic antibiotic
Study: 11048993
Drug: Basiliximab plus
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab plus dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Study: 11048993
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Study: 9066996
Drug: Daily cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cigarette consumption (20 or more cigarettes per day)
Study: 8389026
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 4 mg
Study: 30354996
Drug: Serum TMAO
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum TMAO levels (measured in μmol/L)
Study: 30354996
Drug: Serum TMAO
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum TMAO levels (≥1.79 μmol/L)
Study: 30354996
Drug: Serum TMAO
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum TMAO levels (≥3.19 μmol/L)
Study: 30354996
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between TMAO and folate levels (≥7.7 ng/mL versus <7.7 ng/mL)
Study: 25031198
Drug: liraglutide +
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide + metformin
Study: 24088749
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + metformin
Study: 22499010
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation arm (440 subjects)
Study: 18843900
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 500 mg twice a day for seven days
Study: 18843900
Drug: One vaginal
Normalized name: estrone Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaginal tablet containing freeze-dried Lactobacillus rhamnosus once a week at bedtime for two months starting one week after the last antibiotic administration
Study: 12218528
Drug: Mivacurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.1 mg/kg) immediately after loss of consciousness (Group A)
Study: 10487666
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 6 IU/m2 body surface-day
Study: 10487666
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 3 IU/m2 body surface-day
Study: 8598656
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic compression devices during surgery and 2 days postoperatively (Group 1, n = 25)
Study: 8598656
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5000 U q 12 hr) starting 1 hr before surgery and for 7 days postop (Group 2, n = 38)
Study: 6276949
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous nutrition (PIVN) with chemotherapy (adriamycin, vincristine, VP-16-213, and cyclophosphamide)
Study: 6276949
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous nutrition (PIVN) with chemotherapy
Study: 30232094
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (CGM) with a paper guideline to target glucose control (2.6-10 mmol/L)
Study: 17636113
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg 4 times a day)
Study: 17636113
Drug: Naproxen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (5 mg/kg 4 times a day)
Study: 17636113
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and Naproxen
Study: 10409478
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of sublingual 17beta-oestradiol (E(2))
Study: 6835896
Drug: Intravenous meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meptazinol 100 mg
Study: 26218077
Drug: 5-Azacytidine (5-AZA)
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-Azacytidine (5-AZA) at a dose of 75 mg/m2 s.c. administered on a schedule of 5 days on/weekend off/2 days on (5/2/2)
Study: 24342746
Drug: Hépar 1
Normalized name: Lotilaner (ema epar: veterinary)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hépar 1 group (1 L Hépar and 0.5 L natural low‐mineral water daily)
Study: 24342746
Drug: Hépar 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hépar 0.5 group (0.5 L Hépar and 1 L natural low‐mineral water daily)
Study: 24342746
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.5 L natural low‐mineral water daily)
Study: 19013613
Drug: Contigen injection
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contigen injection
Study: 20439193
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + temozolomide (75 mg/m2/day for 21 or 28 days)
Study: 15607839
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MO)